Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

0.3856 -0.0011 (-0.28%)
Streaming Delayed Price Updated: 10:53 AM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 220,833
Open 0.3754
Bid (Size) 0.3856 (5)
Ask (Size) 0.3857 (2)
Prev. Close 0.3867
Today's Range 0.3754 - 0.3872
52wk Range 0.3450 - 1.620
Shares Outstanding 198,755,831
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
From Ocugen
Via GlobeNewswire

Performance

YTD
-69.15%
-69.15%
1 Month
+4.81%
+4.81%
3 Month
-10.55%
-10.55%
6 Month
-28.15%
-28.15%
1 Year
-75.28%
-75.28%

More News

Read More
Ocugen (OCGN) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Recap: Ocugen Q3 Earnings
Via Benzinga
Earnings Outlook For Ocugen
Via Benzinga
A Preview Of Ocugen's Earnings
Via Benzinga
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Why Is Archer Aviation (ACHR) Stock Moving Today?
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Up 5% Today?
Via InvestorPlace
Exposures COVID-19
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
From Ocugen
Via GlobeNewswire
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
From Ocugen
Via GlobeNewswire
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
From Ocugen
Via GlobeNewswire
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
3 Millionaire-Maker Growth Stocks to Buy Before the Window
Via InvestorPlace
7 Biotech Stocks to Sell in July
Via InvestorPlace
7 Doomed Growth Stocks Destined for Disaster
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.